Press Room

ISPE Annual Meeting

Start
Sunday, October 15, 2023
End
Wednesday, October 18, 2023
Location: Las Vegas, USA

ISPE Annual Meeting offers the opportunity to engage in industry-critical conversations. A comprehensive education program provides attendees with technical sessions on the latest developments in supply chain, operations, facilities, equipment, information systems, product development, production systems, quality systems, regulatory guidance and cutting-edge industry innovations.

On October 17 (11am) Anthony Tantuccio, Fellow Scientist at Hovione, is hosting a presentation on “Continuous Tableting Control Strategies: When and How to Apply Them” where he will share key considerations about appropriate control strategies in CT and how Hovione is positioning itself to enable them. This presentation is included on the topic “Advancements in Drug development and Equipment design”.

Session description:
A CDMO’s role is particularly critical for the adoption of CM in that an equipment standard needs to be established where most of the industry can seamlessly integrate with their own development, manufacturing, and supply chains.

The processes and knowledge of owning and operating the technology must be broad, yet robust, to assure that the benefits outweigh the perceived risks by a meaningful margin. Equally important and fundamental is the control strategy, which provides the final assurance that the chosen manufacturing process is fit for the intended product and will provide the desired quality. It is the fundamental component which is the most challenging to standardize because the drug pipelines are constantly evolving, and demand volumes are volatile these days.

This means it is not possible to have a one-size-fits-all control strategy, that depending on the product lifecycle and the nature of the formulation, the control strategy too may need to be flexible and evolve. This talk will focus on the key themes pertinent to the robust and pragmatic continuous tableting control strategies which Hovione is positioning itself to offer and deploy.

Contact our experts today to find out more aboutContinuous Tableting at Hovione.

Find out more about ISPE 
 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026